MedTrace Logo

LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus

NCT00349986 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2009-12-07

No results posted yet for this study

Summary

The rationale of the study is to determine:

* the first dose and the titration of basal insulin
* the exact daily time administration of basal insulin in poorly controlled type II diabetic patients.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Insuline glargine

Sponsors & Collaborators

Principal Investigators

  • László Erős, MD · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-06-30

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00349986 on ClinicalTrials.gov